Status:
COMPLETED
Language & Cognitive Control
Lead Sponsor:
Donders Centre for Cognitive Neuroimaging
Collaborating Sponsors:
Max Planck Institute for Psycholinguistics
Radboud University Medical Center
Conditions:
Language
Methylphenidate of Undetermined Intent
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Catecholamine (CA) neurotransmitters, such as dopamine (DA) and noradrenaline (NA), have long been implicated playing a critical role in cognitive functions, such as working memory (WM), inhibition, l...
Eligibility Criteria
Inclusion
- Native Dutch speakers
- Right-handed
Exclusion
- Current (or history of) psychiatric disorder (e.g., psychosis, mania, severe depressive disorder)
- Current (or history of) neurological disorder (e.g. m. Parkinson, epilepsy)
- Current (or history of) endocrine / metabolic disorder
- Current (or history of) cardiac or vascular disorder
- Current (or history of) blood illness (e.g. severe anaemia, porphyria)
- Current (or history of) stomach or gastrointestinal tract disease
- History of autonomic failure (e.g., vasovagal reflex syncope)
- Experience of irregular sleep-wake rhythm
- Current (or history of) obstructive respiratory disease
- Current (or history of) clinically significant renal or hepatic disease
- (Recent treatment of) glaucoma
- Current (or history of) drug addiction (e.g. opiate, (meth)amphetamine, lysergic acid diethylamide, cocaine, solvents or barbiturate) or alcohol dependence
- One first degree or two or more second degree family members with a recent treatment of sudden death or ventricular arrhythmia
- Problems swallowing or problems with the oesophagus
- Frequent experience of headrush (vertigo)
- Current experience of an acute serious infection
- First degree family member with schizophrenia or bipolar disorder
- Abnormal hearing or (uncorrected) vision
- Use of psychotropic medication or recreational drugs weekly or more over a period of more than three months in the last 6 months
- Cannabis usage for the last 6 months
- Strong smoking behaviour starting at more than 1 package of cigarettes per week
- Hypersensitivity for e.g. beta blockers or methylphenidate
- Uncontrolled hypertension, defined as diastolic blood pressure at rest \>95 mmHg or systolic blood pressure at rest \>180 mmHg
- Irregular sleep/wake rhythm (e.g. regular nightshifts or cross timeline travel)
- Possible pregnancy or breastfeeding/ inadequate anticonception (for women)
- Lactose intolerance (because the placebo pill will be a lactose product)
- Language related disabilities (e.g. dyslexia, stuttering)
- Daily intense physical training
Key Trial Info
Start Date :
November 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 2 2021
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05272397
Start Date
November 26 2019
End Date
December 2 2021
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging
Nijmegen, Gelderland, Netherlands, 6525EN